Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of denosumab and zoledronic acid.

MLA

Cleeland CS, et al. “Pain Outcomes in Patients with Advanced Breast Cancer and Bone Metastases: Results from a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid.” Cancer (0008543X), vol. 119, no. 4, Feb. 2013, pp. 832–38. EBSCOhost, https://doi.org/10.1002/cncr.27789.

APA

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, & Chung K. (2013). Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer (0008543X), 119(4), 832–838. https://doi.org/10.1002/cncr.27789

Chicago

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, et al. 2013. “Pain Outcomes in Patients with Advanced Breast Cancer and Bone Metastases: Results from a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid.” Cancer (0008543X) 119 (4): 832–38. doi:10.1002/cncr.27789.